Genetic and Histopathological Analysis of a Case of Primary Intraosseous Carcinoma, NOS with Features of Both Ameloblastic Carcinoma and Squamous Cell Carcinoma

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2020 Mar 2

PMID 32113465

Citations 1

Authors

Akane Yukimori

Maiko Tsuchiya

Akane Wada

Yasuyuki Michi

Kou Kayamori

Kei Sakamoto

Tohru Ikeda

Affiliations

Soon will be listed here.

Abstract

Background: Primary intraosseous carcinoma (PIOC), NOS is an odontogenic carcinoma with unknown etiology. Its diagnosis may be used when central jaw carcinoma cannot be categorized as any other type of carcinoma. Further information on this extremely rare tumor is needed to improve our understanding and evaluate the classification of odontogenic carcinomas.

Case Presentation: We herein presented two patients with PIOC, NOS with different clinical and histopathological features and analyzed gene mutations in these patients using next-generation sequencing (NGS). The typical PIOC, NOS case had many histopathological similarities to oral squamous cell carcinoma (OSCC), including the missense point mutations of TP53 Glu285Val, KDR Gln472His, and APC Pro1433Leu, which are similar to those in other cancers; however, no mutations were detected in the other patient with an atypical presentation of PIOC, NOS, which was derived from a precursor cystic lesion with similarities to both ameloblastic carcinoma and OSCC.

Conclusions: Genetic analysis suggested that these two PIOC, NOS cases have different features and can be subcategorized.

Citing Articles

Primary intraosseous carcinoma in the pediatric and adolescent mandible.

Oh H, Shin D, Yoon H, Myoung H, Kim S World J Surg Oncol. 2022; 20(1):25.

PMID: 35086533 PMC: 8793206. DOI: 10.1186/s12957-021-02465-2.

References

Canto A, da Silva Marcelino B, Schussel J, Wastner B, Sassi L, Correa L . Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. Clin Oral Investig. 2018; 23(2):779-784. DOI: 10.1007/s00784-018-2494-y. View

Bhushan N, Rao N, Navatha M, Kiran Kumar B . Ameloblastoma arising from a dentigerous cyst-a case report. J Clin Diagn Res. 2014; 8(5):ZD23-5. PMC: 4080080. DOI: 10.7860/JCDR/2014/5944.4387. View

Kwon J, Jeong B, Yoon Y, Yu C, Kim J . Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring V600E Mutation. J Pathol Transl Med. 2018; 52(3):157-163. PMC: 5964290. DOI: 10.4132/jptm.2018.03.28. View

Kondamari S, Taneeru S, Guttikonda V, Masabattula G . Ameloblastoma arising in the wall of dentigerous cyst: Report of a rare entity. J Oral Maxillofac Pathol. 2018; 22(Suppl 1):S7-S10. PMC: 5824523. DOI: 10.4103/jomfp.JOMFP_197_15. View

Russell-Swetek A, West A, Mintern J, Jenkins J, Rodriguez-Galindo C, Ribeiro R . Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet. 2008; 45(9):603-6. PMC: 3487594. DOI: 10.1136/jmg.2008.059568. View

Sweeney R, McClary A, Myers B, Biscocho J, Neahring L, Kwei K . Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014; 46(7):722-5. PMC: 4418232. DOI: 10.1038/ng.2986. View

Kuan S, Navina S, Cressman K, Pai R . Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol. 2014; 45(3):464-72. DOI: 10.1016/j.humpath.2013.10.026. View

Ohata Y, Kayamori K, Yukimori A, Sumikura K, Ohsako T, Harada H . A lesion categorized between ghost cell odontogenic carcinoma and dentinogenic ghost cell tumor with CTNNB1 mutation. Pathol Int. 2018; 68(5):307-312. DOI: 10.1111/pin.12659. View

Yukimori A, Oikawa Y, Morita K, Nguyen C, Harada H, Yamaguchi S . Genetic basis of calcifying cystic odontogenic tumors. PLoS One. 2017; 12(6):e0180224. PMC: 5489209. DOI: 10.1371/journal.pone.0180224. View

10.

Naruse T, Yanamoto S, Sakamoto Y, Ikeda T, Yamada S, Umeda M . Clinicopathological Study of Primary Intraosseous Squamous Cell Carcinoma of the Jaw and a Review of the Literature. J Oral Maxillofac Surg. 2016; 74(12):2420-2427. DOI: 10.1016/j.joms.2016.05.006. View

11.

Kurppa K, Caton J, Morgan P, Ristimaki A, Ruhin B, Kellokoski J . High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2013; 232(5):492-8. PMC: 4255689. DOI: 10.1002/path.4317. View

12.

Brown N, Rolland D, McHugh J, Weigelin H, Zhao L, Lim M . Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014; 20(21):5517-26. DOI: 10.1158/1078-0432.CCR-14-1069. View

13.

WALDRON C, Mustoe T . Primary intraosseous carcinoma of the mandible with probable origin in an odontogenic cyst. Oral Surg Oral Med Oral Pathol. 1989; 67(6):716-24. DOI: 10.1016/0030-4220(89)90014-5. View

14.

Lo Iacono M, Buttigliero C, Monica V, Bollito E, Garrou D, Cappia S . Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget. 2016; 7(12):14394-404. PMC: 4924723. DOI: 10.18632/oncotarget.7343. View

15.

Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K . Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 2015; 15:908. PMC: 4647703. DOI: 10.1186/s12885-015-1925-2. View

16.

Cousin T, Bobek S, Oda D . Glandular odontogenic cyst associated with ameloblastoma: Case report and review of the literature. J Clin Exp Dent. 2017; 9(6):e832-e836. PMC: 5474343. DOI: 10.4317/jced.53775. View

17.

Nakagaki T, Tamura M, Kobashi K, Koyama R, Fukushima H, Ohashi T . Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget. 2017; 8(35):59113-59122. PMC: 5601718. DOI: 10.18632/oncotarget.19262. View

18.

Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C . Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget. 2016; 8(5):7328-7335. PMC: 5352324. DOI: 10.18632/oncotarget.12551. View